### Location

Biozentrum Spitalstrasse 41, 4056 Basel Switzerland

### Registration




https://www.unispital-basel.ch/en/ueber-uns/forschung-innovation/ innovationsfocus/innovations-focus-zelltherapien - 06.24

SBD

Attendance of this symposium is accredited as continuous medical education for specialists in medical oncology and in hematology.

Credits: SSMO-SGMO: 9 Credits, SGH-SSH: 9 Credits

## Exhibitors



### University Hospital Basel

# Basel Cell Therapy Symposium January 23–24 2025

Biozentrum, Spitalstrasse 41, Basel

organized by Innovation Focus Cell Therapies

# **Program Information**



### **Dear colleagues**

We are very pleased to invite you to the 2nd Basel Cell Therapy Symposium taking place on January 23-24, 2025. This one and half-day meeting aims to discuss current clinical applications and research advances in cell-based therapies. Our ambition is to highlight the innovative promises driven by cell therapies to the broad and diverse scientific community in Switzerland and to promote synergies between academic, clinical and industrial partners.

We look forward to your attendance and contribution to this meeting.

The Innovation Focus Cell Therapies Team

## Program Basel Cell Therapy Symposium 2025

Thursday, 23 <sup>rd</sup> January 2025		
9:00–9:10	Welcome and Keynote Lecture 1 introduction by Mascha Binder (University of Basel and University Hospital Basel)	
9:10–9:15	Introduction	
9:15–10:05	Marcela Maus «Driving CAR-T cells»	
10:10-10:40	Coffee Break and Poster Viewing	
Session 1 «Cell therapy in solid tumours» chaired by Alfred Zippelius and Heinz Läubli (University of Basel and University Hospital Basel)		
10:40-10:45	Introduction	
10:45-11:15	Sebastian Kobold «Engineering T cells to hit cancer vulnerabilities»	
11:20–11:50	Marco Donia «Tumor infiltrating lymphocytes: challenges and opportunities»	
11:55–12:05	Michael T. Sandholzer (University of Basel and University Hospital Basel)	
12:10-12:20	Darya Palianina (University of Basel and University Hospital Basel)	
12:30-14:00	Lunch	
14:00-15:00	Poster Session (with Poster Presenters)	
Session 2 «Cell therapy in haematological tumours» chaired by Jakob Passweg and Nina Khanna (University of Basel and University Hospital Basel)		
15:00-15:05	Introduction	
15:05–15:35	Andrea Schmidts «Engineering new CAR-T platforms»	
15:40–15:50	Melita Irving (University of Lausanne and Lausanne University Hospital)	
15:55–16:05	Tiffany Que (University of Lausanne and Lausanne University Hospital)	
16:05-16:35	Coffee Break and Poster Viewing	
	Awards 2024 chaired by Aleksandra Wodnar-Filipowicz and Jakob Passweg and University Hospital Basel)	
16:40-16:45	Introduction	
16:45-16:55	Winner category Basic Research	
17:00-17:10	Winner category Clinically-oriented Research	
Keynote Lecture 2 chaired by Lukas Jeker (University of Basel and University Hospital Basel)		
17:15–17:20	Introduction	
17:20-18:10	Yvonne Chen «Multi-pronged CAR-T Cells for Cancer Therapy»	
18:10-18:15	Closing remark of the day	

Friday, 24 <sup>th</sup> January 2025		
9:00–9:10	Opening and Keynote Lecture 3 introduction by Andreas Holbro (University Hospital Basel and Blood Donation Center Basel)	
9:10-10:00	Andreas Mackensen: «CAR-T cells in B-cell mediated autoimmune disease »	
10:00-11:00	Coffee Break and Poster Viewing	
	Cell therapy beyond cancer» chaired by Andreas Buser and Andreas Holbro niversity Hospital Basel and Blood Donation Center Basel)	
11:00-11:05	Introduction	
11:05–11:35	Toni Cathomen «Precision Exposed: CRISPR Genotoxicity in Hematopoietic Cell Therapy»	
11:40–12:10	Marc Martinez-Llordella «Development of CAR-Treg therapies to modulate immune responses in transplantation and autoimmunity»	
12:15-12:25	Romina Marone (Basel University Hospital and University of Basel)	
12:30-12:40	Maryam Akrami (Basel University Hospital and University of Basel)	
12:40-12:50	Closing remark of the Symposium by the organizing committee	
12:50-15:00	Apéro (riche)	

#### **Invited Speakers**

**Toni Cathomen,** Professor of Cell and Gene Therapy, Director Institute for Transfusion Medicine and Gene Therapy, Medical Center – University of Freiburg, Freiburg, Germany.

**Yvonne Chen,** Professor, Department of Microbiology, Immunology, and Molecular Genetics and Department of Chemical and Biomolecular Engineering, University of California-Los Angeles (UCLA), Los Angeles, CA, USA. Co-director of the Tumor Immunology program of the UCLA Jonsson Comprehensive Cancer Center. Member Researcher of the Parker Institute for Cancer Immunotherapy Center at UCLA.

**Marco Donia**, Associate Professor in Clinical Oncology, University of Copenhagen, Denmark. Research Group Leader, Department of Oncology, National Center for Cancer Immune Therapy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.

**Sebastian Kobold,** Professor of Medicine and Experimental Immuno-oncology, Deputy Director and Attending Physician, Division of Clinical Pharmacology, Faculty of Medicine, Department of Medicine IV, University Hospital of Ludwig-Maximilian University Munich (LMU), Munich, Germany. Research Group Leader of Immunopharmacology, Division of Clinical Pharmacology, Ludwig-Maximilian-University Munich, Munich, Germany.

**Marcela Maus,** Professor at Harvard Medical School, the Paula O'Keefe Chair in Oncology. Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center. Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy, division of Oncology at MGH. Associate Member of the Broad Institute of Harvard and MIT. Associate Member of the Ragon Institute of MGH, MIT, and Harvard.

Andreas Mackensen, Director of the Dept. of Internal Medicine 5 - Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany.

Marc Martinez-Llordella, Vice President, Biology, Quell Therapeutics Ltd, London, UK.

Andrea Schmidts, Emmy Noether Research Group Leader at the Department of Medicine III, Hematology/ Oncology, Technical University of Munich, Munich, Germany.